A new era of cancer detection: Why and how clinicians are implementing MCED
Today, routine cancer screening in the U.S. is recommended for only four cancers: breast, colorectal, cervical and, for high-risk patients, lung. Yet nearly 70% of annual U.S. cancer cases and deaths come from cancers no broad guideline tells clinicians to screen for — among them pancreatic, ovarian and esophageal.
Multi-cancer early detection (MCED) tests are starting to close that gap. Using a single blood draw, they can help screen for dozens of cancer types and subtypes before symptoms appear.
This report distills insights shared at Becker's 16th Annual Meeting, where clinical and informatics leaders described how they are putting MCED testing into routine practice — what convinced them, how they handle positive results and what it takes to fit a new test into a clinical workflow.
Inside, you'll learn:
Multi-cancer early detection (MCED) tests are starting to close that gap. Using a single blood draw, they can help screen for dozens of cancer types and subtypes before symptoms appear.
This report distills insights shared at Becker's 16th Annual Meeting, where clinical and informatics leaders described how they are putting MCED testing into routine practice — what convinced them, how they handle positive results and what it takes to fit a new test into a clinical workflow.
Inside, you'll learn:
- Where current screening guidelines leave the widest gaps, and which cancers go undetected
- How the test profiled performs: 64% overall sensitivity in the indicated use population, 97.4% specificity and 68% sensitivity for the six deadliest cancers
- How one practice integrated direct order entry and bidirectional results into its EHR
- How clinicians communicate and act on positive results
Please fill out the form to download the whitepaper.